Was There Exposure? Objective Tests Through Advances in Biomarker Science Relevant to Asbestos and Other Toxic Tort Litigation

Posted by Giovanni Ciavarra on Tue, Jan, 10, 2017

This article was authored by Giovanni Ciavarra, PhD and Kirk Hartley, Esq.  This post previously appeared on The Goldberg Segalla Asbestos Case Tracker.

Read More

WEBINAR: Genetic Susceptibility, Exposure Markers, and the Talc Experience

Posted by David Schwartz on Tue, Jan, 03, 2017

Innovative Science Solutions will be speaking at the upcoming Toxic Torts and Product Liability Webinar to be hosted by Mayer Brown on Thursday, January 19, 2017 (1:00 p.m. – 2:30 p.m. EST).

 

Emerging Science and Toxic Tort Litigation: Genetic Susceptibility, Exposure Markers, and the Talc Experience

 

The webinar features a presentation by Dr. Suresh Moolgavkar -- a renowned expert focused on supporting legal cases involving carcinogenesis -- and will focus on the use of scientific data in personal injury litigation involving talc. Fueled by several recent multimillion dollar verdicts, lawsuits by people with mesothelioma or ovarian cancer who allege prior talc exposure as a cause have been on

Read More

Does Carcinogenicity Classification Make Any Sense?

Posted by David Schwartz on Tue, Dec, 20, 2016

In a recent trial involving allegations that asbestos-contaminated talc caused the plaintiff’s mesothelioma (the Lamonica case), plaintiff counsel (Scott Frost) was having a difficult time impeaching the opinions of the defense pathologist (Dr. Mossman). After spending some time trying to impeach her opinions based on her financial payments, Frost turned to another tried and true tactic: attempt to gain the admission that talc was classified by a government agency as carcinogenic.

Read More

Jurors in Toxic Tort Litigation Take Genetic Issues Seriously

Posted by David Schwartz on Tue, Dec, 13, 2016

This article was authored by David Schwartz, PhD and Kirk Hartley, Esq.  This post previously appeared on The Goldberg Segalla Asbestos Case Tracker.

Read More

The Increasing Relevance of Social Media to Adverse Drug Reaction Reporting

Posted by David Schwartz on Tue, Dec, 06, 2016

Adverse event data from protocol-driven, controlled clinical trials forms the backbone of any rigorous safety assessment on a new drug product. Nevertheless, lawyers defending pharmaceutical agents in product liability litigation must maintain a detailed awareness of spontaneously reported adverse events associated with drug exposures. As part of this effort, a good litigator must develop an understanding of what FDA says about the risks of specific drugs.

Read More

Findings From The Bias and Conflict of Interest WORKSHOP

Posted by Giovanni Ciavarra on Wed, Nov, 30, 2016

Recently, the workshop on Bias and Conflict of Interest that we discussed in a previous blog post was held in Luxembourg.

Read More

Five Reasons You Need a “Fox” in Science-Based Litigation

Posted by Giovanni Ciavarra on Thu, Nov, 17, 2016

About 50 years ago, Isaiah Berlin wrote about two kinds of thinkers in the world: hedgehogs and foxes. According to Berlin, Hedgehogs know one big thing, while foxes dart from idea to idea. In our view, this metaphor serves to illustrate how litigators think about their expert teams.

Read More

Big Data and New Technology - ISS Presenting at The 10th Annual Gibbons E-Discovery Conference

Posted by David Schwartz on Tue, Nov, 15, 2016

Dr. David Schwartz of Innovative Science Solutions will be presenting at the upcoming 10th Annual Gibbons E-Discovery Conference being held in West Orange (New Jersey) on November 18, 2016. 

Read More

Follow the Science Not the Money

Posted by David Schwartz on Tue, Sep, 27, 2016

This post was authored by Joseph Huggard, the General Manager of The Huggard Consulting Group who has spent more than 20 years working on a broad range of high profile issues with a particular emphasis on the use and communication of robust science, better regulation and regulatory impact assessment. Joe is highly regarded for his establishment of panels with high levels of scientific expertise and integrity which have produced influential findings on a variety of difficult issues.

Read More

The Future of Asbestos Litigation - Linking Genomic Science with Rigorous Exposure Assessment

Posted by David Schwartz on Thu, Sep, 15, 2016

The vast majority of malignant mesothelioma (MM) cases are asbestos related, yet the majority of individuals exposed to asbestos (even relatively high doses of amphibole asbestos fibers) do not develop MM. Many have concluded from this observation that there may be some genetic factor or factors that make some individuals more prone to mesothelioma than others -- perhaps even predestined to developing MM, even in the absence of asbestos exposure.

Read More
Blog Search

Blog Subscription